Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of QAB149 in COPD
NCT00129831Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2004
- Primary completion
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of indacaterol in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Primary endpoint: Safety variables (laboratory tests, ECG, adverse events). Started Sep 2004; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00129831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129831.